Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 11/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298353 | 0.85 | NPC1 (0.42) | NPC1PIK3CDOXTRAVPR1AGCGR | |
| SCHEMBL4390296 | 0.77 | PSEN1 (0.43) | NPC1GCGRNOTUM | |
| SCHEMBL21507851 | 0.77 | PTGDR2 (0.50) | CYP2A6 | |
| SCHEMBL10899210 | 0.75 | AHR (0.52) | NPC1PIK3CDCYP2A6 | |
| SCHEMBL4727663 | 0.70 | TRPV3 (0.44) | NPC1PIK3CDCYP2A6NOTUM | |
| SCHEMBL14681833 | 0.70 | CTRC (0.48) | CNR2 | |
| SCHEMBL1742300 | 0.69 | PIK3CD (0.61) | NPC1PIK3CDCYP2A6NOTUMMAP4K4 | |
| SCHEMBL11831790 | 0.69 | CBFB (0.47) | NPC1 | |
| SCHEMBL14686350 | 0.69 | MAPT (0.43) | NOTUM | |
| SCHEMBL1662273 | 0.69 | PIK3CD (0.73) | NPC1PIK3CDCYP2A6NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741316-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6872717-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ACHARD DANIEL (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | NPC1 1086/4885PIK3CD 946/4885OXTR 767/4885 |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | NPC1 1086/4885PIK3CD 946/4885OXTR 767/4885 |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | CHRM2, ACHE, DRD2 | NPC1 977/4885PIK3CD 4561/4885OXTR 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.